Hyundai Bioscience Co. Ltd (048410) — Cash Flow-to-Debt Ratio
Hyundai Bioscience Co. Ltd (048410) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of ₩-2.05 Billion could theoretically repay 0% of its total liabilities (₩17.12 Billion) in one year. Explore Hyundai Bioscience Co. Ltd (048410) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hyundai Bioscience Co. Ltd Cash Flow-to-Debt Ratio (2008–2025)
Historical debt coverage capacity for Hyundai Bioscience Co. Ltd across 14 annual periods. Also explore how large is Hyundai Bioscience Co. Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hyundai Bioscience Co. Ltd (2008–2025)
Year-by-year debt coverage analysis for Hyundai Bioscience Co. Ltd. For market capitalisation and broader financial context, see Hyundai Bioscience Co. Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.85x | ₩-17.05 Billion | ₩20.01 Billion | ▼ -1167.0% |
| 2024 | 0.08x | ₩2.26 Billion | ₩28.27 Billion | ▲ +110.0% |
| 2023 | -0.80x | ₩-6.01 Billion | ₩7.52 Billion | ▲ +56.1% |
| 2022 | -1.82x | ₩-16.54 Billion | ₩9.09 Billion | ▼ -6306.3% |
| 2021 | -0.03x | ₩-538.48 Million | ₩18.96 Billion | ▼ -115.6% |
| 2020 | 0.18x | ₩7.50 Billion | ₩41.09 Billion | ▼ -67.7% |
| 2019 | 0.57x | ₩9.18 Billion | ₩16.25 Billion | ▲ +52.7% |
| 2018 | 0.37x | ₩5.01 Billion | ₩13.52 Billion | ▲ +286.3% |
| 2017 | -0.20x | ₩-3.70 Billion | ₩18.61 Billion | ▼ -61.0% |
| 2016 | -0.12x | ₩-4.34 Billion | ₩35.17 Billion | ▼ -2756.0% |
| 2015 | 0.00x | ₩87.36 Million | ₩18.81 Billion | ▼ -96.1% |
| 2014 | 0.12x | ₩1.22 Billion | ₩10.32 Billion | ▼ -51.3% |
| 2011 | 0.24x | ₩3.97 Billion | ₩16.30 Billion | ▼ -12.7% |
| 2008 | 0.28x | ₩10.37 Billion | ₩37.17 Billion | — |